NDAORALTABLET
Approved
Mar 2020
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
11
Mechanism of Action
inhibitor. It inhibits 11beta-hydroxylase (CYP11B1), the enzyme responsible for the final step of cortisol biosynthesis in the adrenal gland. In a Chinese hamster lung cell line V79-4 that overexpresses human CYP11B1, adrenodoxin and adrenodoxin reductase, osilodrostat inhibited the activity of…
Clinical Trials (5)
Osilodrostat in Patients With Hypertension Caused by Hypercortisolaemia Due to Cushing's Syndrome
Started Aug 2026
63 enrolled
HypertensionHypercortisolemiaCushing Syndrome
Isturisa Treatment in Mild Autonomous Cortisol Secretion( MACS)
Started Feb 2026
10 enrolled
Mild Autonomous Cortisol Secretion (MACS)
Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)
Started Jan 2026
15 enrolled
Mild Autonomous Cortisol SecretionAutonomous Cortisol Secretion (ACS)
A Block-and-Replace Therapy With Osilodrostat and Concomitant Glucocorticoid Replacement
Started Jul 2024
12 enrolled
Endogenous Cushing SyndromeAdrenal InsufficiencyHypercortisolism
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
Started Jan 2023
103 enrolled
Cushing's Syndrome
Loss of Exclusivity
LOE Date
Oct 12, 2035
116 months away
Patent Expiry
Oct 12, 2035
Exclusivity Expiry
Mar 6, 2027